A recent study shows that multiple sites of extramedullary-bone related (EMB) lesions are poor prognostic factors for newly diagnosed multiple myeloma (MM). The results appeared in Frontiers in Oncology.
This was retrospective study in which investigators assessed the baseline characteristics and prognosis of 357 newly diagnosed patients with extramedullary multiple myeloma (EMM).
According to the results, compared to patients without EM, patients with EMM had worse progression-free survival (PFS) (P = 0.014) and overall survival (OS) (P = 0.032). In addition, the researchers noted, patients without EM and those with a single site of EMB had similar PFS and OS, while patients with multiple sites of EMB or EME and multiple sites of EMB with EME had poor PFS and OS.
“This study suggested that among patients treated with bortezomib-based regimens, multiple sites of EMB and/or EME are independent poor prognostic factors for newly diagnosed MM patients, while a single site of EMB does not affect the survival of newly diagnosed MM patients.,” the researchers concluded.
They added that “these findings could be used as a reference for the study of EMM patients in the new drug era, but prospective clinical studies are needed to provide evidence-based data for the diagnosis and treatment of EMM.”